BDTX Financials Black Diamond Therapeutics, Inc.
8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $70M | $22.4B | 0.0% | 17.9% | 19933.0% | 15640.2% | — | — | $21M |
| 2024 | $0 | -$69.7B | — | — | -83659.7% | -56813.4% | -$62M | — | $36M |
| 2023 | — | -$82M | — | — | -70.6% | -52.0% | -$67M | — | $56M |
| 2022 | — | -$91M | — | — | -78.8% | -58.3% | -$85M | — | $34M |
| 2021 | — | -$126M | — | — | -64.1% | -50.7% | -$103M | — | $66M |
| 2020 | — | -$67M | — | — | -21.9% | -20.4% | -$52M | — | $35M |
| 2019 | — | -$35M | — | — | 74.8% | -22.3% | -$25M | — | $155M |
| 2018 | — | -$9M | — | — | 57.5% | -17.2% | -$9M | — | $52M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$10M | — | — | -10.3% | -7.9% | — | — | $19M |
| Mar '26 | $0 | -$9M | — | — | -8.7% | -6.8% | — | — | $30M |
| Dec '25 | $0 | -$15M | — | — | -13.5% | -10.6% | — | — | $21M |
| Sep '25 | $0 | -$8M | — | — | -6.7% | -5.4% | — | — | $31M |
| Jun '25 | $0 | -$11M | — | — | -8.0% | -6.3% | — | — | $30M |
| Mar '25 | $70M | $57M | 0.0% | 77.9% | 40.0% | 32.1% | — | — | $98M |
| Dec '24 | $0 | -$16M | — | — | -19.2% | -13.0% | -$15M | — | $36M |
| Sep '24 | $0 | -$16M | — | — | -16.0% | -11.3% | — | — | $23M |
| Jun '24 | $0 | -$20M | — | — | -18.0% | -13.3% | — | — | $33M |
| Mar '24 | $0 | -$18M | — | — | -17.5% | -12.8% | — | — | $25M |
| Dec '23 | — | -$19M | — | — | -16.6% | -12.2% | -$14M | — | $56M |
| Sep '23 | — | -$23M | — | — | -17.1% | -13.3% | -$18M | — | $58M |
| Jun '23 | — | -$19M | — | — | -23.3% | -16.0% | -$14M | — | $42M |
| Mar '23 | — | -$21M | — | — | -21.3% | -15.4% | -$20M | — | $39M |
| Dec '22 | — | -$21M | — | — | -18.2% | -13.5% | -$22M | — | $34M |
| Sep '22 | — | -$22M | — | — | -16.3% | -12.0% | -$16M | — | $54M |
| Jun '22 | — | -$23M | — | — | -15.0% | -11.5% | -$18M | — | $56M |
| Mar '22 | — | -$26M | — | — | -14.8% | -11.6% | -$29M | — | $54M |
| Dec '21 | — | -$26M | — | — | -13.2% | -10.4% | -$24M | — | $66M |
| Sep '21 | — | -$35M | — | — | -16.0% | -12.8% | -$28M | — | $47M |
Valuation over time
How the market has priced BDTX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 2.0× (Dec '25) to 1.7× (Sep '26).
Frequently asked questions
Is BDTX growing its revenue and profit?
See the revenue and net-income charts above for Black Diamond Therapeutics, Inc.'s multi-year trend.
How much debt does BDTX have?
As of FY2025, Black Diamond Therapeutics, Inc. reported — of total debt against $21M of cash.
What is BDTX's profit margin?
In FY2025, gross margin was —, operating margin 17.9%, and net margin 31952.9%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.